Journal of psychopharmacology (Oxford, England)

Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.

Journal of psychopharmacology (Oxford, England) 2023 Brent M Kious, Zach Schwartz, Benjamin R. Lewis 44 citations

Psychedelic research is proceeding rapidly, despite ongoing legal and regulatory barriers and lingering questions about study design, such as the difficulty of ensuring adequate blinding, the relative overrepresentation in studies of participants who have previously used psychedelics, and the importance of personal experience with psychedelics for those who provide psychedelic-assisted therapy....

DOI: 10.1177/02698811221133461 Full text MDMA Psilocybin Research ethics Research-ethics +4

A narrative synthesis of research with 5-MeO-DMT.

Journal of psychopharmacology (Oxford, England) March 1, 2022 Anna O. Ermakova, Fiona Dunbar, James Rucker et al. 83 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring, short-acting psychedelic tryptamine, produced by a variety of plant and animal species. Plants containing 5-MeO-DMT have been used throughout history for ritual and spiritual purposes. The aim of this article is to review the available literature about 5-MeO-DMT and inform subsequent clinical development. We searched PubMed...

DOI: 10.1177/02698811211050543 Full text 5-methoxy-n N-dimethyltryptamine Ego-dissolution Classic psychedelic +10

The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects.

Journal of psychopharmacology (Oxford, England) March 1, 2022 Malin Vedøy Uthaug, Alan K. Davis, Trevor Forrest Haas et al. 64 citations

Mescaline is a naturally occurring psychoactive phenethylamine found in several cacti and historically used ceremonially by Indigenous and Latin American populations. Broader recognition of its possible therapeutic value in Western science began in the 1950s; however, knowledge of the safety profile of mescaline and the extent of its use remains limited. The primary aim of this study is to...

DOI: 10.1177/02698811211013583 Full text Mescaline 3,4,5-trimethoxyphenethylamine Epidemiology

Challenges in translational research: MDMA in the laboratory versus therapeutic settings.

Journal of psychopharmacology (Oxford, England) March 1, 2022 Harriet de Wit, Anya K. Bershad, Charles S. Grob 11 citations

Despite substantial progress in the use of mind-altering drugs to treat psychiatric disorders, the psychological processes through which these drugs change mood or behavior are poorly understood. Controlled laboratory studies with well-defined psychological constructs are valuable to understand how these drugs manifest their therapeutic benefit. However, there are substantial methodological...

DOI: 10.1177/02698811211015221 Full text Mental disorders MDMA Trials Psychedelic research Ecstasy research +12

A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties.

Journal of psychopharmacology (Oxford, England) August 1, 2021 Rachael Sumner, Emme Chacko, Rebecca McMillan et al. 68 citations

Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. The aim of the current study was to explore the psychedelic experiences and sustained impact of ketamine in major depressive disorder. In the...

DOI: 10.1177/0269881121998321 Full text Ketamine Depression Psychedelic Qualitative research +1

Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial.

Journal of psychopharmacology (Oxford, England) February 1, 2021 Rebecca L Rothberg, Nour Azhari, Nancy A Haug et al. 95 citations

Sub-anesthetic ketamine administration may be helpful for substance use disorders. Converging evidence suggests that the efficacy of ketamine for certain conditions may implicate a subset of its psychoactive effects. The aim of this analysis is to evaluate whether the mystical-type effects of ketamine are critical for clinical efficacy in alcohol-dependent individuals. In this secondary...

DOI: 10.1177/0269881120970879 Full text Ketamine Alcohol use disorder Mystical experience Addiction treatment +5

Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale.

Journal of psychopharmacology (Oxford, England) February 1, 2021 Dylan Truppman Lattie, Hayley Nehoff, Shona Neehoff et al. 13 citations

Ketamine has rapid anxiolytic effects in treatment-resistant obsessive compulsive, post-traumatic stress, generalised anxiety and social anxiety disorders. This study aimed to assess changes following acute and maintenance ketamine therapy on the Fear Questionnaire (FQ) subscales and the Spielberger State Anxiety Inventory (SSAI). This secondary analysis used data from a mixed open-label and...

DOI: 10.1177/0269881120953991 Full text Ketamine Anxiety Fear questionnaire Phobia

Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects.

Journal of psychopharmacology (Oxford, England) September 1, 2020 Alan K. Davis, John Clifton, Eric G Weaver et al. 144 citations

Experiences of having an encounter with seemingly autonomous entities are sometimes reported after inhaling N,N-dimethyltryptamine. The study characterized the subjective phenomena, interpretation, and persisting changes that people attribute to N,N-dimethyltryptamine-occasioned entity encounter experiences. Two thousand, five hundred and sixty-one individuals (mean age 32 years; 77% male)...

DOI: 10.1177/0269881120916143 Full text DMT Phenomenology N,N-Dimethyltryptamine Psychedelic experiences +19

Temporal dissociation of phencyclidine: Induced locomotor and social alterations in rats using an automated homecage monitoring system - implications for the 3Rs and preclinical drug discovery.

Journal of psychopharmacology (Oxford, England) July 1, 2020 Emma J Mitchell, Ros R Brett, J Douglas Armstrong et al.

Rodent behavioural assays are widely used to delineate the mechanisms of psychiatric disorders and predict the efficacy of drug candidates. Conventional behavioural paradigms are restricted to short time windows and involve transferring animals from the homecage to unfamiliar apparatus which induces stress. Additionally, factors including environmental perturbations, handling and the presence...

DOI: 10.1177/0269881120920455 Full text Homecage Autism Locomotor activity Phencyclidine +4

Why do people use new psychoactive substances? Development of a new measurement tool in six European countries.

Journal of psychopharmacology (Oxford, England) June 1, 2020 Annemieke Benschop, Róbert Urbán, Máté Kapitány-fövény et al. 35 citations

New psychoactive substances (NPS) pose a public health threat. Many studies have tried to identify the reasons of NPS use; however, none of them have so far used any standardised measures. The aim of this study was (i) to develop and cross-culturally validate the New Psychoactive Substance Use Motives Measure (NPSMM) and (ii) to compare motives of NPS use across countries and user types. Three...

DOI: 10.1177/0269881120904951 Full text New psychoactive substances Cross-national validation Measurement

Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.

Journal of psychopharmacology (Oxford, England) September 1, 2019 James D. Sexton, Michael S Crawford, Noah W Sweat et al. 33 citations

Novel psychedelics approximate classic psychedelics, but unlike classic psychedelics, novel psychedelics have been used by humans for a shorter period of time, with fewer data available on these substances. The purpose of this study was to determine the prevalence of novel psychedelic use and the associations of novel psychedelic use with mental health outcomes. We estimated the prevalence of...

DOI: 10.1177/0269881119827796 Full text Hallucinogen Mental health Phenethylamines Novel psychedelic use +1

Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol.

Journal of psychopharmacology (Oxford, England) September 1, 2019 Elisa Pabon, Harriet de Wit

Acute consumption of cannabis or its primary psychoactive ingredient ∆9-tetrahydrocannabinol has been shown to impair memory, reaction time, time perception, and attention. However, it is difficult to measure these impairments in a brief test that can be used in a non-laboratory setting. We aim to develop and validate a prototype for a mobile phone application to measure...

DOI: 10.1177/0269881119862533 Full text Cannabis Marijuana Driving Dronabinol +1

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.

Journal of psychopharmacology (Oxford, England) December 1, 2018 Marcela Ot'Alora G, Jim Grigsby, Bruce Poulter et al. 232 citations

Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Twenty-eight...

DOI: 10.1177/0269881118806297 Full text Serotonin 3,4-Methylenedioxymethamphetamine MDMA Oxytocin Posttraumatic stress disorder +16

The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Journal of psychopharmacology (Oxford, England) July 1, 2018 Alan K. Davis, Joseph P Barsuglia, Rafael Lancelotta et al. 137 citations

5-Methoxy- N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in several plants and in high concentrations in Bufo alvarius toad venom. Synthetic, toad, and plant-sourced 5-MeO-DMT are used for spiritual and recreational purposes and may have psychotherapeutic effects. However, the use of 5-MeO-DMT is not well understood. Therefore, we examined patterns of use, motivations for...

DOI: 10.1177/0269881118769063 Full text 5-Methoxy-N,N-Dimethyltryptamine 5-MEO-DMT 5-Methoxy-N Psychoactive tryptamines Compound +9

Psychedelics and hypnosis: Commonalities and therapeutic implications.

Journal of psychopharmacology (Oxford, England) July 1, 2018 Clément E Lemercier, Devin B. Terhune

Recent research on psychedelics and hypnosis demonstrates the value of both methods in the treatment of a range of psychopathologies with overlapping applications and neurophenomenological features. The potential of harnessing the power of suggestion to influence the phenomenological response to psychedelics toward more therapeutic action has remained unexplored in recent research and thereby...

DOI: 10.1177/0269881118780714 Full text Consciousness Hypnosis Psychedelics Psychotherapy +1

Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy.

Journal of psychopharmacology (Oxford, England) August 1, 2017 Mark T Wagner, Michael C Mithoefer, Ann T Mithoefer et al. 163 citations

A growing body of research suggests that traumatic events lead to persisting personality change characterized by increased neuroticism. Relevantly, enduring improvements in Post-Traumatic Stress Disorder (PTSD) symptoms have been found in response to 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. There is evidence that lasting changes in the personality feature of "openness"...

DOI: 10.1177/0269881117711712 Full text MDMA Neo personality Openness Pharmacotherapy +10

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.

Journal of psychopharmacology (Oxford, England) July 1, 2016 Deborah C. Mash, Barbara Ameer, Delphine Prou et al. 29 citations

This study investigated the effects of noribogaine, the principal metabolite of the drug ibogaine, on substance-related disorders. In the first experiment, mice chronically treated with morphine were subjected to naloxone-precipitated withdrawal two hours after oral administration of noribogaine. Oral noribogaine dose dependently decreased the global opiate withdrawal score by up to 88% of...

DOI: 10.1177/0269881116641331 Full text Cns drugs Blood–brain barrier Conditioned place preference Drug brain penetration +5

Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Journal of psychopharmacology (Oxford, England) April 1, 2016 Matthew W Johnson, Katherine A Maclean, Michael J Caspers et al. 11 citations

Salvinorin A is a kappa opioid agonist and the principal psychoactive constituent of the Salvia divinorum plant, which has been used for hallucinogenic effects. Previous research on salvinorin A pharmacokinetics likely underestimated plasma levels typically resulting from the doses administered due to inefficient vaporization and not collecting samples during peak drug effects. Six healthy...

DOI: 10.1177/0269881116629125 Full text Salvia divinorum Salvinorin a Cortisol Endocrine +17

Up: The rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use.

Journal of psychopharmacology (Oxford, England) April 2016 Stephen J. Kaar, Jason Ferris, Jon Waldron et al.

In recent years the recreational use of inhaled nitrous oxide gas (N2O) is becoming increasingly popular, yet little is known about the characteristics of its users or the effects they experience. This paper presents original research from the 2014 Global Drug Survey (GDS) (n=74,864). GDS runs the largest survey of recreational drug use in the world. The findings confirm N2O as a very common...

DOI: 10.1177/0269881116632375 Full text Nitrous oxide Addictions Anaesthetic Drugs of misuse +1

Noribogaine reduces nicotine self-administration in rats.

Journal of psychopharmacology (Oxford, England) June 1, 2015 Qing Chang, Taleen Hanania, Deborah C. Mash et al. 26 citations

Noribogaine, a polypharmacological drug with activities at opioid receptors, ionotropic nicotinic receptors, and serotonin reuptake transporters, has been investigated for treatment of substance abuse-related disorders. Smoking cessation has major benefits for both individuals and society, therefore the aim of this study was to evaluate the potential of noribogaine for use as a treatment for...

DOI: 10.1177/0269881115584461 Full text Food self-administration Nicotine addiction treatment Noribogaine pharmacology Behavioral specificity

The subjective experience of acute, experimentally-induced Salvia divinorum inebriation.

Journal of psychopharmacology (Oxford, England) April 1, 2015 Peter H. Addy, Albert Garcia‐romeu, Matthew Metzger et al. 38 citations

This study examined the overall psychological effects of inebriation facilitated by the naturally-occurring plant hallucinogen Salvia divinorum using a double-blind, randomized, placebo-controlled trial. Thirty healthy individuals self-administered Salvia divinorum via combustion and inhalation in a quiet, comfortable research setting. Experimental sessions, post-session interviews, and 8-week...

DOI: 10.1177/0269881115570081 Full text Salvia divinorum Salvinorin a Hallucinogens Kappa +6

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.

Journal of psychopharmacology (Oxford, England) March 1, 2015 Peter S. Hendricks, Christopher B Thorne, C Brendan Clark et al. 377 citations

Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over...

DOI: 10.1177/0269881114565653 Full text Lysergic acid diethylamide Psilocybin Psychedelic Hallucinogen +3

Treating drug dependence with the aid of ibogaine: a retrospective study.

Journal of psychopharmacology (Oxford, England) November 1, 2014 Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, Bruno Rasmussen Chaves et al. 110 citations

Ibogaine is an alkaloid purported to be an effective drug dependence treatment. However, its efficacy has been hard to evaluate, partly because it is illegal in some countries. In such places, treatments are conducted in underground settings where fatalities have occurred. In Brazil ibogaine is unregulated and a combined approach of psychotherapy and ibogaine is being practiced to treat...

DOI: 10.1177/0269881114552713 Full text Dependence Cocaine Crack Ibogaine treatment +1

The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.

Journal of psychopharmacology (Oxford, England) August 1, 2014 Will Lawn, Monica J Barratt, Martin L Williams et al.

The NBOMe compounds are a novel series of hallucinogenic drugs that are potent agonists of the 5-HT2A receptor, have a short history of human consumption and are available to buy online, in most countries. In this study, we sought to investigate the patterns of use, characteristics of users and self-reported effects. A cross-sectional anonymous online survey exploring the patterns of drug use...

DOI: 10.1177/0269881114523866 Full text Demographics Nbome Hallucinogen Internet drug market +8

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.

Journal of psychopharmacology (Oxford, England) 2013 Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer et al. 377 citations

We report follow-up data evaluating the long-term outcomes for the first completed trial of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for chronic, treatment-resistant post-traumatic stress disorder (PTSD) (Mithoefer et al., 2011). All of the 19 subjects who received MDMA-assisted treatment in the original trial participated in the long-term follow-up (LTFU), with 16 out of...

DOI: 10.1177/0269881112456611 Full text Psychedelic therapy MDMA-Assisted Psychotherapy MDMA Therapy Ecstasy therapy +18

Papers